OSPREY trial reports non-inferior results of RTH258 in treatment of wet AMD

DENVER — Repeat doses of RTH258 may effectively treat neovascular age-related macular degeneration, according to a presentation here at the Association for Research in Vision and Ophthalmology annual meeting.Lawrence J. Singerman, MD, and colleagues conducted the OSPREY trial, a randomized, double-masked, active-controlled study of 89 patients with AMD to evaluate the safety and efficacy of repeat doses of 6 mg of RTH258 (Alcon) vs. 2 mg of Eylea (aflibercept, Regeneron) over 56 weeks.